Xenadrine EFX manufacturer settles with FTC
This article was originally published in The Tan Sheet
Executive Summary
RTC Research and Development and the company's executives, husband and wife Robert Chinery Jr. and Tracy Chinery, settle in a case brought by the Federal Trade Commission for charges of false and unsubstantiated weight-loss claims related to their supplement Xenadrine EFX. In an April 24 release. FTC says it charged the defendants in 2005, and in 2006 the U.S. District Court for the District of New Jersey barred Robert Chinery and RTC from making claims and required RTC pay $8 million in consumer redress (1"The Tan Sheet" Aug. 13, 2007, In Brief). Tracy Chinery's motion to dismiss a similar settlement was denied in July 2007 and her motion for summary judgment was denied in March 2009, FTC says. The final settlement prohibits the Manasquan, N.J.-based firm and the Chinerys from "making any claims about the health benefits, performance, efficacy, safety, or side effects of any weight-loss product, dietary supplement, food, drug, or device" unless substantiated, true and not misleading. FTC says the defendants are not required to provide additional redress